Fifteen normal male volunters received 400, 800, and 1200 mg doses of ibuprofen as 1, 2, or 3 tablets, respectively, in crossover fashion
in the treatment of arthritis. Its biological properties (1, 2), metabolism (3) , and binding to albumin (4, 5) have been described. Two GLC assay methods (6, 7) and several HPLC assay methods (8) (9) (10) (11) (12) (13) (14) have been reported. We have described an HPLC assay for ibuprofen and its major metabolites in biological fluids (15) . Whitlam et al. (16) described the transsynovial distribution of ibuprofen in arthritic patients. Steady et al. (17) reported on the bioavailability of the drug in man following administration as tablets. In the first article in this series (18), we described a 15 subject study in young adults in which the subjects received 400, 800, and 1200 mg doses of ibuprofen as 1, 2, and 3 tablets, respectively, in crossover fashion one week apart; then on the fourth week all subjects received a dose of 420 mg of the drug in the form of an aqueous solution. Two other articles in this series have been published (19, 20) . Kearns and Wilson (14) administered 400mg of sodium ibuprofen intravenously over a 5 min period to a dog. They fitted the post infusion data to a biexponential equation and modeled disposition of the drug using an open two compartment model. Unfortunately, to date there is no intravenous dosage form of ibuprofen available for use in man. In this article we infer the disposition model of ibuprofen in man from total plasma concentrations following administration of a 420 mg dose in the form of the aqueous solution. In addition, a new absorption equation (21) , applicable to the open two compartment model, was applied to total plasma concentrations following administration of the different doses in tablet form to the young adults to produce absorption plots for ibuprofen in man.
EXPERIMENTAL PROCEDURE

Studies in Man
Fifteen Caucasian male subjects with mean age 25 (range 22-35) years and mean body weight 78 (range 70-92.5) kg were selected from respondents to an advertisement based on subject availability, reliability, medical history, physical examination, and results of blood and urinary analyses. In crossover fashion they were dosed with 1, 2, or 3 commercial 400 mg ibuprofen tablets (Motrin; Upjohn) with treatments one week apart. In the fourth week, all subjects received a 420 mg dose in the form of an aqueous solution of ibuprofen. Following tablet treatments blood was collected at 0, 0.167, 0.333, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hr, and following solution treatment, blood was collected at 0, 0.0833, 0.167, 0.25, 0.333, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hr. The sampling schemes for tablets and solution were different because the drug was absorbed appreciably faster following administration of the solution than following the tablets. Blood was converted to plasma immediately after collection, frozen, and stored in the freezer at -10~ until just prior to assay. Plasma was assayed for total ibuprofen by the HPLC assay described formerly (15) .
Data Analysis
Individual subject sets of concentration-time (C,t) data were fitted to a triexponential equation using the method of least squares in a program written by Dr. Jeffrey Fox and an Apple II microcomputer. Initial estimates were obtained with Dr. Fox's program, called RSa-RIP, also using the microcomputer. Both arithmetic and geometric mean plasma concentrations of the 15 subjects following the solution were fitted by the same procedure using equal, 1/Y and 1/Y 2 weights for different fits to provide six different triexponential equations.
For those data sets which gave a triexponential equation such that the negative coefficient, -(BI + B2), was associated with the largest exponent, ka, the absorption rate constant, then the model of Scheme I was assumed, and the parameters k~2, k21, kez, and Vp were estimated from the three coefficients, three exponents, and the dose using the equations of Wagner (22) . The new "Exact Loo-Riegelman" equation of Wagner (21) (2) Vp and the fraction of drug absorbed, Fa, is given by
Initially, in evaluating C,t data following tablets, Eqs. (1) and (2) were applied using the k12, k21, and kel values derived from solution data via the triexponentail fitting. However, in almost all cases the AT/Vp values increased with time then decreased, or the values kept increasing throughout most of the time sampling. It was found that these trends were indicative that the wrong rate constants were being employed in Eq. (1), and they were "wrong" as a result of intrasubject variation, particularly in k12 and k21. Hence, a new procedure was evolved to derive the constants from terminal C,t data of the same data set to which Eq. (1) was applied to the initial C,t data.
The new procedure involved the assumption that Vp is constant intrasubject for solution and tablet treatments and that absorption following both solution and tablet treatments is complete. Bioavailability of ibuprofen from tablets relative to the solution was discussed in a previous article (18) . The procedure is as follows. Vp is estimated from solution data using
Here D~ is the dose of ibuprofen (420 mg) administered in solution form, kit is the first order model elimination rate constant (Scheme I) estimated from the triexponential fit of the solution C,t data, and (AUC 0-oo)s is the total area under the C,t curve following the solution.
Terminal C,t data from 3 to 12 hr following a tablet treatment were fitted to the biexponential equation (Eq. 5) by the same procedure as described above to obtain the triexponential fits of solution data for 0-8 hr (Eq. 6) where to is the lag time:
It should be noted that pharmacokinetic theory indicates that the magnitudes of B~ and B2 in Eqs. (5) and (6) are different. However, A1 and ~2 would be the same if there was no intrasubject variation, but of different magnitudes if there was intrasubject variation in the parameters kl2 , k21 , and ke~. The model rate constants were estimated from tablet data using Eqs. (7)- (9). In these equations,
V;(AUC 0-oo),
Dt is the dose if ibuprofen is administered as tablets, Vp is from Eq. (4), (AUC 0-~)t is the total area under the C,t curve following the tablet treatment and A1 and A2 are from Eq. (5). The values of kt12, k~l, ktel obtained from Eqs. (7)- (9) were then substituted into Eq. (1), and Eq. (1) was applied to the C,t data in the 0-3 hr time range of the same data set which gave Eq. (5) in the 3-12 hr range.
In some cases (see note a of Table liD , terminal tablet C,t data were fitted very well with only a monoexponential rather than a biexponential equation. In these cases, the Wagner-Nelson method (24) was applied rather than the method described herein using Eqs. (1)- (5) and (7)- (9). In some cases Eqs. (5) and (7)- (9) led to negative values of Ul2. Attempts were then made to calculate a different kte~ value using Eq. 10 from Dittert et al. (23) ,
where A~ is from the mono-or biexponential fit of terminal tablet C,t data. When solution C,I data were computer-fitted with the triexponential Eq. (6), an estimate of k~, the absorption rate constant, was obtained. Hence, the fraction absorbed, F~, following administration of the solution, could be described by Eq. (11) . Values of F~ obtained with F~ = 1-e -k,,(t-t~ (11) were compared with values of F, obtained from applications of Eqs.
(1)-(3).
In the computer fitting of C,t data, three measures of fit were employed.
These were as follows. The coefficient of determination, r 2, was obtained from Eqs. (12)- (14), where aThis gave a triexponential equation of the form of Eq. (22), whereas the other subjects gave equations of the form of Eq. (6).
S 2 is the corrected sum of squares of the observed concentrations, C, and kc C is the model-predicted concentrations (from either Eq. 5 or 6). Corr. is the correlation coefficient for the linear regression of C on C. The standard deviation, S, was estimated with
where N is the number of data points fitted, and P is the number of parameters estimated, namely, 4 for Eq. (5) and 6 for Eq. (6). The weighting scheme which gave the smallest Y, d 2, and hence the smallest value of S (Eq. 15), and largest value of r 2 (Eq. 12) was chosen (Tables I and II) . Table I lists results of fitting solution C,t data of 13 individual subjects to the triexponential Eq. (6). The type of weighting, namely equal, 1/Y and 1/y2, which gave the best fit is indicated in the second column of Table I . The estimated parameters A1, A2, ka, and to (but not B1 and B2) are listed as well as the measures of fit obtained with Eqs. (12)- (15) . In the last four columns are listed the derived parameters Vp, k~2, k~, and kSt; note that A~ < k21 < A2 < ka. These fittings indicate that the model of Scheme I is the appropriate model and the model of Scheme II is the disposition model. (Table II) . Figure 1 shows a typical triexponential fit of solution C,t data (for subject # 2). The fitting of typical terminal tablet C,t data to a biexponential equation is also shown in the lower panel of Fig. 1. Figure 2 is a plot of Fa values for the solution estimated with Eq. (I)-(3) using the k~2, k~l, and kit values listed in Table I vs. Fa values obtained with Eq. (11) using the ko and to values from the triexponential fittings listed in Table I . Figure 2 is based on the pooled data of the 13 subjects whose triexponential equation had the form of Eq. (6). This is evidence that Eqs. (1)- (3) provide accurate values of fraction of ibuprofen absorbed. The least squares line had a slope of 1.045, which did not differ significantly from unity, and an intercept of -0.0059, which did not differ significantly from zero, with r = 0.980. In Fig.  2 , the line of identity with a slope equal to unity is drawn. Figure 3 is a plot of Fa versus time for the solution of ibuprofen showing data for subject # 9, who absorbed drug from the solution the most rapidly, and that for subject # 7, who absorbed the drug from solution the slowest. The points in the plots were obtained with Eqs. Terminal C,t data following the ibuprofen solution were also fitted to biexponential equations (Eq. 5), and Eqs. (7)-(9) were then applied to generate k~2, k~l, and k~l values (rather than the kt12, k~l, and ktet as in Eqs. 7-9). These were different values than those listed in Table I . The two sets of microscopic rate constants for the solution were then used, separately, in Eqs. (1)-(3) to generate two sets of FaT values. In Fig. 4 , Fa from the biexponential fit is plotted vs. Fa from the triexponential fit. The least squares line had a slope of 1.096, which was not significantly different from unity, and an intercept of -0.039, which was not significantly different from zero, with r = 0.972. The line drawn through the points is the line of identity with slope equal to unity. This figure provides support for the fitting of terminal C,t data to biexponential equations in order to estimate the h~ and A2 values from which k~2 and k2~ values could be estimated. Table III lists the estimated parameters and measures of fit of terminal tablet C,t data to monoexponential or biexponential equations. These were excellent fits.
RESULTS
The apparent elimination rate constants (A0 obtained in the monoexponential or biexponential fittings (for treatments with 1, 2, or 3 tablets) and triexponential fittings (solution data) are listed in Tables I and III Table 1 for estimated parameters and measures of fit). Lower panel: typical biexponential fit of terminal C,t tablet data. Table I ). This is excellent evidence to support the new absorption equation (Eq. 1). The least squares line for the data is Y=-1.045X-0.0059 with r = 0.980. Line is identity with slope equal to unity (see text).
solution obeys first order kinetics (Fig. 3) , absorption of the drug following tablets is not simple first order. Following one 400 mg tablet, the absorption plots are S-shaped (Fig. 5) as Digenis (25) reported using scintography. Following the 800 mg two tablet dose, there begins to be evidence of some zero order absorption (Fig. 6) . Following the 1200 mg three tablet dose, the evidence for zero order absorption becomes more pronounced (Fig. 7) . In the first article (18) it was reported that ibuprofen exhibits nonlinear plasma protein binding and that a plot of the area under the total (bound + free) plasma concentration-time curve was a nonlinear function of the mg/kg dose of the drug; however, a plot of the area under the free (unbound) plasma concentration-time curve was essentially linear. Linearity of such plots implies constant plasma clearance. Although the average bound/free ratio of ibuprofen in the study under discussion (18) was 180, almost all the observed binding values were in the lower one-third of the overall binding curves. Hence, although the data were nonlinear, they were minimally so. Although we believe that input kinetics should be determined from total plasma concentrations of drug even in cases of such nonlinearity, one may ask what would happen if free concentrations were similarly analyzed. We have done so with the free ibuprofen plasma concentrations using the same methods as used for total concentrations. Free plasma concentrations following the solution of ibuprofen were computer-fitted to Eq. (6); rate constants, ka, could be compared in 13 of the 15 subjects. The mean kt~ from total concentrations, 6.76 hr -1, did not differ significantly from the mean k~ from free concentrations, 6.07hr -1 (paired t= 1.89, O.lO>p > 0.05); least squares linear regression of Y= k] from free vs. was not significantly different from zero, with r=0.973 (p <0.001). Thus, results obtained by analyzing free concentrations were essentially the same as those obtained by analyzing total concentrations. In addition, intrasubject variation of pharmacokinetic parameters derived from free concentrations were of the same magnitude as those derived from total concentrations.
DISCUSSION
Although first order absorption is often assumed in pharmacokinetics, there are few examples in the literature where there is convincing evidence of this. We have shown that ibuprofen administered orally in the form of an aqueous solution was absorbed according to first order kinetics in 14 of 15 subjects. This was shown in two different ways: (a) by computer fitting C,t data following the solution to a triexponential equation, which was based upon first order absorption; and (b) by applying a new absorption equation (21) using the microscopic rate constants k~2, k~l, and k~, which were derived from the triexponential fit. A new method has been described to obtain absorption plots for a multicompartmental system without intravenous data. The method is based on estimating Vp following administration of the drug in solution form, fitting terminal C,t data following tablet(s) to a biexponential equation (Eq. 5), then estimating the microscopic rate constants, k'~2, k;~, and k'e~ (using Eqs. 7-9), followed by application of a new absorption equation (Eq. 1). The method is valid if the absorption following solution and tablet forms to the same subject is complete in both cases. The method was successfully applied to ibuprofen C,t tablet data. The new method was developed since the usual assumption of the constancy of the distribution rate constants, kl2 and k2i, of the open two compartment model was found to be invalid in the case of ibuprofen. Although such constancy has hitherto been assumed in the case of application of the Loo-Reigelman method (26), the assumption has never been well tested.
A most interesting result of the analyses of the ibuprofen data is that the pharmacokinetic model which one would elaborate from mean C,t 14 out of 15 sets of individual subject data. Both the arithmetic and geometric mean data were fitted by a triexponential equation in which the coefficient with a negative sign was associated with the intermediate-sized rate constant. However, in 14 out of 15 sets of individual subject C,t ibuprofen solution data, the coefficient with a negative sign was associated with the largest rate constant. The methods discussed in this article have been applied successfully to results obtained in a similar study with flurbiprofen, and those results will be the subject of a future publication.
